Many studies have reported the influence of the immune microenvironment on BC occurrence and immunotherapy, including the long-term application of Bacillus subtilis Calmette-Guerin and PD-1/PD-L1 blockers in treating BC (Eich et al., 2019). This evidence concerns the gene CD274 and breast cancer.